Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 346

1.
2.

Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers.

Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R.

J Rheumatol. 2001 Mar;28(3):514-9.

PMID:
11296951
4.

The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.

Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR.

J Rheumatol. 2001 Dec;28(12):2637-43.

PMID:
11764209
5.

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.

Calvo-Alén J, Toloza SM, Fernández M, Bastian HM, Fessler BJ, Roseman JM, McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS; LUMINA Study Group.

Arthritis Rheum. 2005 Jul;52(7):2060-8.

7.

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM.

Arthritis Rheum. 2009 Jan 15;61(1):29-36. doi: 10.1002/art.24232.

8.

Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis.

Kaplanski G, Cacoub P, Farnarier C, Marin V, Grégoire R, Gatel A, Durand JM, Harlé JR, Bongrand P, Piette JC.

Arthritis Rheum. 2000 Jan;43(1):55-64.

9.
10.

Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus.

Kuryliszyn-Moskal A, Klimiuk PA, Ciolkiewicz M, Sierakowski S.

J Rheumatol. 2008 Jul;35(7):1307-13. Epub 2008 May 15.

PMID:
18484695
11.

Strong association of autoantibodies to human nuclear lamin B1 with lupus anticoagulant antibodies in systemic lupus erythematosus.

Senécal JL, Rauch J, Grodzicky T, Raynauld JP, Uthman I, Nava A, Guimond M, Raymond Y.

Arthritis Rheum. 1999 Jul;42(7):1347-53.

12.
13.
14.

Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.

Danowski A, de Azevedo MN, de Souza Papi JA, Petri M.

J Rheumatol. 2009 Jun;36(6):1195-9. doi: 10.3899/jrheum.081194. Epub 2009 May 15.

PMID:
19447935
15.

Plasma thrombomodulin as an indicator of thromboembolic disease in systemic lupus erythematosus.

Ohdama S, Yoshizawa Y, Kubota T, Aoki N.

Int J Cardiol. 1994 Dec;47(1 Suppl):S1-6.

PMID:
7737745
16.

Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.

Kuryliszyn-Moskal A, Ciolkiewicz M, Klimiuk PA, Sierakowski S.

Scand J Rheumatol. 2009 Jan-Feb;38(1):38-45. doi: 10.1080/03009740802366050.

PMID:
18991188
17.

Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus.

Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Garmendia M, Gabriel Erdozain J, Villar I, Aguirre C.

Lupus. 2007;16(10):810-6.

PMID:
17895304
18.

Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state.

Ferro D, Pittoni V, Quintarelli C, Basili S, Saliola M, Caroselli C, Valesini G, Violi F.

Circulation. 1997 Mar 18;95(6):1425-32.

19.

Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.

Figueredo MA, Rodriguez A, Ruiz-Yagüe M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, Patiño R.

J Rheumatol. 2006 Oct;33(10):1980-6.

PMID:
17014014

Supplemental Content

Support Center